RJA
IRD

Raymond James & Associates’s Opus Genetics IRD Stock Holding History

Raymond James & Associates’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$15.4K Buy
+11,758
New +$18.1K ﹤0.01% 3959

Other funds holding IRD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
RB
Richmond Brothers Jackson, Michigan $150M AUM 14.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Raymond James & Associates's IRD Position: Q3 2024 in Review

Raymond James & Associates opened a new position in Opus Genetics (IRD) in Q3 2024: 11,758 shares worth $15.4K. The stake represents ﹤0.01% of the portfolio and ranks #3959 among its holdings.

38 funds tracked by Wall St. Rank hold IRD as of Q3 2024.

  • Raymond James & Associates held 11,758 shares of Opus Genetics worth $15.4K as of Q3 2024.
  • Opus Genetics was a new Raymond James & Associates position in Q3 2024.
  • Opus Genetics made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #3959 holding.
  • 38 funds tracked by Wall St. Rank held Opus Genetics as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.